AbbVie vs. CVS Health: Which Healthcare Stock Is a Better Buy in 2026?

Investors often weigh high-margin drug developers against massive healthcare service providers when building a portfolio. Choosing between AbbVie (NYSE:ABBV) and CVS Health (NYSE:CVS) requires balancing biotech growth against retail stability.

AbbVie focuses on discovering and commercializing advanced therapies, while CVS Health operates an integrated model spanning insurance, pharmacies, and primary care clinics. Both companies play critical roles in the healthcare sector but offer very different risk and reward profiles for retail investors seeking long-term exposure in the current market.

The case for AbbVie

AbbVie operates as a global biopharmaceutical giant among healthcare stocks, selling advanced therapies to wholesale distributors and government agencies. Its primary customers include McKesson, Cardinal Health, and Cencora, which represent nearly all U.S. sales. Customer concentration like this adds a layer of risk to the business. The company recently moved to strengthen its pipeline by announcing a $10.9 billion acquisition of Apogee Therapeutics in June 2026.

In FY 2025, revenue reached nearly $61.2 billion, which was an increase of roughly 8.6% compared to the prior year. Net income for the period was close to $4.2 billion, reflecting a net margin of approximately 6.9%. While revenue grew, the net margin saw a slight decline from the 7.6% reported in the previous fiscal year. Net margin is a simple way to measure how much of every dollar in sales a company keeps as profit.

As of its December 2025 balance sheet, the debt-to-equity ratio was -21.1x. This negative figure indicates that total liabilities exceed shareholder equity. The current ratio, which measures a company's ability to pay short-term debts with short-term assets, was close to 0.7x. Free cash flow for FY 2025 was nearly $17.8 billion. Free cash flow is the cash left over after a company pays for its operations and equipment.

The case for CVS Health

CVS Health serves approximately 37 million medical members through employer groups and government plans like Medicare Advantage. The company manages 1.9 billion prescriptions annually through its Health Services segment and operates a network of roughly 63,000 pharmacies. Its primary care centers, including Oak Street Health, work with over 25 different payors to provide value-based care. This vertical integration allows the business to capture revenue at multiple points in the patient journey.

In FY 2025, revenue reached approximately $402.1 billion, representing growth of nearly 7.8% over the prior year. Net income for the period was close to $1.8 billion, resulting in a net margin of roughly 0.4%. This net margin is significantly lower than the 1.2% recorded in FY 2024. Net margin represents the percentage of revenue remaining after all expenses and taxes are paid, indicating how much profit is generated from total sales.

As of the December 2025 balance sheet, the debt-to-equity ratio was approximately 1.2x. This ratio compares a company's total debt to the value of its shareholder equity to show how much leverage it uses. The current ratio was nearly 0.8x, suggesting the company has $0.80 in short-term assets for every $1.00 in short-term debt. Free cash flow for FY 2025 was roughly $7.8 billion, which represents cash generated after accounting for capital investments.

Risk profile comparison

AbbVie faces significant risks from patent expirations and competition from biosimilars, particularly for its former blockbuster drug Humira. The business also deals with revenue concentration in its newer products, Skyrizi and Rinvoq, as competitors like Pfizer develop competing immunology treatments. Furthermore, drug pricing legislation and the Inflation Reduction Act have led to government price setting for several key products. Complex global regulations and a 2026 lawsuit regarding drug discount programs add further uncertainty.

CVS Health operates in highly competitive industries where price compression often affects its pharmacy and insurance segments. The company faces pressure from Walgreens Boots Alliance in the retail space and UnitedHealth Group in the insurance market. Heavy exposure to government programs makes it vulnerable to policy changes and audits by the Centers for Medicare and Medicaid Services. Legal challenges remain a factor, including a $440 million False Claims Act settlement in 2026 regarding its Omnicare subsidiary.

Valuation comparison

CVS Health appears to be the more conservative value play based on its lower multiples, while AbbVie demands a premium for its specialized pharmaceutical portfolio.

Valuation metrics sourced from Financial Modeling Prep (FMP) and may differ from other data providers.

Which stock would I buy in 2026?

I'd go with AbbVie, although CVS Health deserves credit for a genuine turnaround in progress. The company beat estimates by a wide margin in its most recent quarter and raised its full-year outlook for the second time this year. Its troubled Aetna insurance business is finally showing signs of stabilization. For investors who want broad healthcare exposure at a modest valuation, CVS has become a more interesting story than it has been in a while.

But AbbVie is running a more focused operation with a more exciting growth trajectory. Skyrizi and Rinvoq are each growing at an extraordinary pace, and the Humira biosimilar headwind is largely behind the company now. The company also has a neuroscience portfolio that is accelerating in ways that most investors have underappreciated. AbbVie raised its full-year outlook for the second time this year and pays one of the more attractive dividends in the healthcare sector.

CVS is a turnaround story that appears to be working, but AbbVie is a growth story that is already delivering. For a long-term investor, that distinction makes AbbVie the easier stock to own right now.

Sara Appino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbbVie and Pfizer. The Motley Fool recommends CVS Health and McKesson. The Motley Fool has a disclosure policy.